Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).
Jyoti D. Patel
No relevant relationships to disclose
Edward B. Garon
Research Funding - Lilly
Ramaswamy Govindan
Consultant or Advisory Role - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Honoraria - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Craig H. Reynolds
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - Lilly
David R. Spigel
Consultant or Advisory Role - Lilly
Mark R. Olsen
No relevant relationships to disclose
Robert C. Hermann
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Lilly; Roche
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Susan C. Guba
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Eduardo J. Pennella
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Coleman K. Obasaju
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Philip D. Bonomi
Consultant or Advisory Role - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly